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CLINICAL INVESTIGATION
Chiorthalidone promotes mineral retention in patients with
idiopathic hypercalciuria
FREDRIC L. COE, JOAN H. PARKS, DAVID A. BUSHINSKY, CRAIG B. LANGMAN,
and MURRAY J. FAVUS
Renal Program, Pritzker School of Medicine, University of Chicago, and Children's Memorial Hospital,
Northwestern University, Chicago, Illinois, USA
Chiorthalidone promotes mineral retention in patients with idiopathic
hyperealciuria. In seven patients with severe idiopathic hypercalciuria
and recurrent calcium oxalate nephrolithiasis, we have determined the
effects on mineral balance of chronic treatment with chlorthalidone or
trichlormethiazide, drugs that are widely used to lower urine calcium
losses and reduce stone recurrence. Each person excreted above 350
mg of calcium daily while untreated, and was studied twice, before and
after three to six months of treatment. Compared to pretreatment, the
drugs reduced intestinal calcium absorption; but they reduced urine
calcium loss even more, so calcium retention increased. Phosphate
retention also increased. Serum levels of calcitriol, parathyroid hor-
mone, calcium, phosphate, and magnesium were unchanged. At least in
patients of this type, chlorthalidone and trichlormethiazide seem ideal
treatments, that lower urine calcium yet increase calcium and phos-
phate retention. Whether patients with less severe hypercalciuria
respond this way is unknown.
At least half of all patients with calcium oxalate stones have
a normocalcemic form of hypercalciuria [1] called idiopathic
because its cause is not yet firmly established, though it is
familial [21 and probably inherited [31. 1-lypercalciuria promotes
calcium stones by raising urine calcium oxalate supersaturation
14]; and treating hypercalciuria with thiazide diuretics, that
lower urine calcium excretion [4], reduces stone formation
impressively [5]. Although our knowledge of pathogenesis is
incomplete, some characteristics of these patients are estab-
lished: their intestinal calcium absorption is above normal [6];
during fasting or low calcium diet a large fraction of patients
loses more calcium in their urine than normal people [7]; serum
levels, and production of calcitriol are elevated in some patients
[8]; and serum levels of parathyroid hormone (PTH) vary from
low to high [9]. One formulation is that hypercalciuria fre-
quently is due to calcitriol excess [10], but primary intestinal
calcium overabsorption [9] and a renal tubule defect of calcium
reabsorption [9] both have strong experimental support.
Because thiazide type diuretics lower urine calcium excretion
at least partly by increasing renal tubule calcium reabsorption
[11], they can influence calcium balance depending upon how
they affect intestinal calcium absorption. If the drugs reduce
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calcium absorption as part of their hypocalciuric action, cal-
cium retention could increase, fall, or remain constant. Calcium
retention must increase if intestinal calcium absorption does not
fall.
Response of calcium absorption and retention to thiazide
type diuretics is not established, because past results have been
variable and contradictory. In four studies that have used
balance techniques [12—15] to study 15 patients with idiopathic
hypercalciuria [12—14] and 5 normal children [15], calcium
absorption rose in 4 patients, was unchanged in S patients, and
fell in 6 patients and all S normal children. Calcium retention
rose in 13 of 15 patients, and fell in 2 patients and all 5 children.
When measured using isotope methods [16—19] in patients with
idiopathic hypercalciuria, intestinal calcium absorption fell in
26, was constant in 28, and rose in 4 patients; retention could
not be calculated.
Because past results have been variable, especially between
studies, we have examined the effects of one particular thiazide
type diuretic, chlorthalidone, on calcium and phosphorus bal-
ance of six adult patients with calcium oxalate stones and
severe hypercalciuria, and a similar patient taking trichlor-
methiazide. Patients who have very severe hypercalciuria, like
these we have chosen, seem most likely to receive thiazide type
diuretics; when they do, the absolute fall in urine calcium from
the drug will be larger than in patients with lower calcium
losses, or in normal subjects. We found, in this highly selected
group, that the drugs always increased calcium and phosphorus
retention.
Methods
Patients and protocol
Our seven patients (3 women) each had formed many calcium
oxalate renal stones, and excreted more than 350 mg of calcium
daily in their urine (Table 1). Their calcium and phosphate
balances were measured during six days in our Clinical Re-
search Center, and then they were treated with chlorthalidone,
50 to 100 mg daily (Table 1), or trichlormethiazide, 6 mg daily
(patient 6), along with sufficient potassium to maintain serum
levels. After about three months (Table 1), calcium and phos-
phate balances were measured again. No other medications
were used. The patients who had been taking a thiazide type
diuretic stopped it three to four weeks (Table I) before the first
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Table 1. Outpatient values on free-choice diet of seven severe hypercalciuric calcium oxalate stone formers
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 All
Sex F M M F M M F
Age at study 61 41 57 45 39 51 54 50 3
Months (T-C) 3 6 6 4 4 3 6 4.6 0.5
Dose CTD 50 mg 50 mg 100 mg 50 mg 50 mg 6 mg* 50 mg
BMD 1.103 1.233 1.021 1.001 1.306 1.043 0.779 1.042 0.08
Z score —0.8 —.0 —1.1 —2.2 0.8 —1.3 —2.6 —1.18 0.60
%Age matched 91.7 99.6 87.7 77.9 109.0 85.9 69.7 88.8 4.9
Serum
calcium 9.67 0.07 9.71 0.06 9.70 0.05 9.21 0.10 9.79 0.07 9.26 0.12 9.92 0.06 9.61 0.06
magnesium 1.96 0.01 2.20 0.03 2.10 0.02 2.14 0.04 2.20 0.02 — 1.93 0.02 2.09 0.03
phosphorus 2.99 0.12 2.84 0.28 3.77 0.11 2.35 0.17 2.37 0.20 3.03 0.08 3.09 0.05 2.96 0.03
creatinine 0.73 0.01 1.13 0.04 0.96 0.06 0.78 0.02 0.85 0.02 1.01 0.02 0.76 0.02 0.89 0.03
uric acid 4.24 0.08 6.32 0.41 5.31 0.10 3.89 0.32 4.30 0 5.43 0.16 3.85 0.19 4.84 0.22
Urine
pH-24 hr 4.65 0.02 6.27 0.09 6.53 0 6.58 0.03 5.80 0.03 6.43 0.08 6.07 0.21 5.97 0.16
volume-24 hr 1.26 0.05 3.03 0.12 3.64 0.12 3.44 0.18 1.58 0.16 2.99 0.14 2.06 0.23 2.64 0.19
creatinine 1.32 0.04 2.03 0.06 1.82 0.03 1.45 0.01 2.05 0.16 1.91 0.05 1.05 0.03 1.68 0.08
sodium 179 20 202 27 201 14 225 18 293 33 174 13 210 10 210 10
calcium 407 73 495 41 472 66 365 4 443 65 410 19 401 21 426 18
citrate 999 48 787 55 — 418 43 712 10 — 629 85 709 55
oxalate 34 1 43 2 — 35 5 37 2 — 33 2 37 I
phosphate 1.32 0.05 1.24 0.03 1.01 0.04 0.68 0.30 1.29 0.06 0.92 0.07 0.94 0.11 1.05 0.06
magnesium 128 20 152 6 144 1 111 17 113 20 — 102 4 124 7
uric acid 503 83 816 49 836 63 677 29 855 41 695 53 557 27 699 35
Abbreviations are: Pt, patient; CTD, chlorthalidone, or in one patient(*), trichiormethiazide; months (T-C), time period in months between 2
CRC admissions; BMD, bone mineral density measured by dual photon absorptiometry, expressed in grams/cm2; Z score, Z-score vs. age and sex
matched controls; % Age matched, percent of BMD expected for sex and age matched normals. Serum values are mg/dl, urine are mg/24 hr except
for sodium, mEq/24 hr. All are Patients 3 and 6 had been on a thiazide type diuretic before the study; Patient 3 discontinued it 4 weeks prior
to the first CRC admission, patient 6 had discontinued it 3 weeks prior to the first CRC admission.
balance study. Bone mineral density measured by dual photon
absorptiometry (Lunar Radiation Corporation, Madison, Wis-
consin, USA) and presented as g/cm2, and as percent of age
matched normals, and in standard deviation units (Z scores):
difference from the age matched normal mean divided by the
standard deviation of the measurements.
Balance was measured on a diet calculated to be isocaloric to
their normal intakes and providing (per/kg body wt/24 hr)
calcium, 10 to 12 mg (0.25 to 0.30 mmol), phosphate 20mg (0,21
mmol), and sodium 2 mEq. The diet was provided as frozen
meals for use at home for seven days prior to admission, then
continued in the Clinical Research Center for six more days
during which all urine and stool was collected. The patients ate
one of two fixed menus alternated daily for variety. The actual
mineral contents of each batch of each diet were determined by
direct measurement, using the techniques we also applied to
stool. Polyethylene glycol (PEG, molecular wt 4000) was given
beginning three days before admission, and continued during
the balance study. Blood was drawn on days 1, 3 and 7 of the
admission, for calcium, phosphate, magnesium and calcitriol;
parathyroid hormone (PTH), ionized calcium, electrolytes in-
cluding sodium, potassium, bicarbonate and chloride, and
arterialized venous pCO2 and pH were measured on day 7only.
Measurements
Stool. Each 24 hour collection was pooled and weighed,
placed in a plastic bag, and homogenized (Stomacher Lab
Blender, Tekmar, Cincinnati, Ohio, USA) in 1000 to 3000 ml of
deionized water containing 4.0 ml octanol to minimize foaming.
Ten ml aliquots were transferred into glass bottles. 10 ml of
perchioric acid:nitric acid (1:1) were added and samples were
incubated in a water bath at 70°C for three hours. At that time
an additional 5.0 ml of the acid was added [20], the final volume
was adjusted to 25 ml with deionized water, the sample was
centrifuged, and the supernatant diluted 50-fold for analysis of
calcium and phosphate. This extraction technique was also
used to prepare diet samples for mineral measurements. In
preliminary studies, recovery of calcium by the addition of 45Ca
to the homogenate was 97% to 104%. Polyethylene glycol was
measured in duplicate by the method of Malawer and Powell
[21], and used to determine completeness of collection.
Chemistry measurements. Calcium and magnesium in serum
and urine, and stool calcium, were measured by atomic absorp-
tion spectrophotometry (Model 22, Instrument Laboratories,
Andover, Massachusetts, USA) using aqueous standards. Ion-
ized calcium was measured by micro-electrode (Orion Biomed-
ical Space Stat 0; Orion Research Inc., Cambridge, Massachu-
setts, USA) [221. Phosphate and creatinine were measured by
autoanalyzer methods, sodium and potassium by flame photom-
etry, pH and PCO2 using a blood gas instrument (Radiometer
BMS MK 2), and bicarbonate was calculated [231.
Calcitriol. Calcitriol serum levels were measured by radio-
receptor assay. Briefly, one ml aliquots of frozen serum were
thawed at room temperature and equilibrated with 1500 cpm of
3H- 1 ,25(OH)2D3 (160 Ci/mmol, Amersham Searle, Arlington
Heights, Illinois, USA) for 15 minutes to monitor procedural
losses. I ,25(OH)2D3 was separated from serum lipids and other
vitamin D metabolites by extraction with acetonitrile followed
by sequential elution from C-l8 Sep Pak (Waters Associates,
Medford, Massachusetts, USA) with water, methanol:water
70:30 and acetonitrile and from silica Sep Pak with hexane:
isopropanol 96:4 and 85:15. The fraction containing 1,25
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a mid molecule antibody (43 to 68 residue recognition Incstar,
1000 Stillwater, Minnesota, USA) and human PTH (MFR) for stan-
dard curves. Least detectable level was 11 prvi, 144 Mper tube
gave a 50% displacement. Intra-assay coefficient of variation
was 1%. Each of the day seven serum samples was assayed in
quadruplicate. For this assay, the normal range is 24 to 86 M
100 (Fig. IA), and the assay differentiates hypoparathyroid, vitamin
D deficient patients, and patients with end-stage chronic renal
failure, and chronic renal failure from normal. In samples from
four normal adults whose blood ionized calcium level was
varied by infusion of calcium or EDTA (Fig. IB), serum PTH
10 varied log linearly with blood ionic calcium level.
Analysis
Calcium and phosphate intakes were calculated from the
amounts of food eaten and the diet calcium and phosphate
contents. Unconsumed food was weighed and subtracted from
the amount given. Since the diets were isocaloric to their
normal intakes and people slightly underestimate their intake,
everyone ate virtually all of the food presented, leaving little or
no correction for unconsumed food at each meal. Total fecal
calcium and phosphate for the six days was corrected by
multiplying our measured values by the ratio of PEG in the six
days of collection to the amount consumed; percent PEG
recovery varied from 67 to 113. Total urine calcium and
phosphate were measured and used without correction. For
each subject, we calculated balance as the difference between
total calcium and phosphate consumed, and calcium and phos-
phate lost in stool and urine during the six days. Net absorption
was the difference between total calcium and phosphate con-
sumed and that lost in the stool over the six days. Effects of the
drug were estimated by subtracting for each patient the total
intakes and excretions of calcium and phosphate during the
control period from corresponding values during the treatment
period. Mean differences were calculated for the seven sub-
jects, and the hypothesis that mean differences were zero tested
by 1-tests [25]. Calcium and phosphate excretions, and serum
levels are presented in mg/dl which is common usage; balance
data are in mmol, to simplify comparisons of calcium and
phosphate retentions.
Results
Calcium and phosphate balances
Thiazide reduced urine calcium losses in all patients (Fig. 2,
shaded portions of bars); and although fecal calcium (clear
portions of bars) increased in five of the seven patients, urine
calcium fell much more, so calcium retention (the distance
between the bottom of each bar and the zero reference hori-
zontal line) rose. Average fecal calcium loss for the group
increased only 32% as much as urine calcium fell (Fig. 3), so
calcium retention increased by an average of 13.25 mmol per six
days (P < 0.01 vs. 0). Among individuals (Table 2), sodium
excretion was constant between control and thiazide periods, as
was body weight and urine volume.
Urine phosphate fell in six of the seven patients (Fig. 4), and
since fecal losses were constant, retention increased. Average
phosphate retention increased by 8.1 mmol/6 days (Fig. 5). In
all seven patients, changes in calcium and phosphate retention
were in the same direction (Fig. 6); for reference the graph
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Fig. IA. Serum PT!-! levels in normal people and patients with clinical
disorders, Values are confidence limits. Hypo, hypoparathyroid-
sm 6 pts; CTL, normal subjects, 35 people; -D, nutritional vitamin D
deficiency, 9 pts; CR1, chronic renal insufficiency, serum creatinine 1.5
to 5 mg/dl, 42 pts; ESRD, 14 patients receiving hemodialysis for end
stage chronic renal failure. B. Response of serum PTH to altered blood
calcium ioii. Calcium ion level was altered in 4 normal adults by
infusion of calcium chloride or EDTA. Regression slope is 40± pM/mM,
intercept, 77 psi, r = —0.597, p < 0.001.
(OH)2D3 eluted from the silica Sep Pak was evaporated under
nitrogen and redissolved in a small volume of 95% ethanol. A
portion was used to determine recovery and the remainder was
assayed in triplicate in the radioreceptor assay that uses
l,25(OH)D receptor from calf thymus [24]. All six samples
(three from each of the two balance periods) from each subject
were analyzed in the same assay. Overall sample recovery was
53 6% for three assays. The least detectable dose ranged from
0.4 to 1.2 pg/assay tube, and the 50% displacement of the assay
curve was 12 to IS pg/assay tube. Intra-assay coefficient of
variation was 4.5% and inter-assay coefficient for the three
assays was 6.9%. Healthy adults age 18 to 50 years had higher
circulating levels (29 14 pg/mI, mean SD, N = 47) than
healthy adults above age 50 years (22 II, N = 69). Patients
with primary hyperparathyroidism had higher serum 1,25
(OH)2D3 levels (40 29, N 16) than normals. Those with
postmenopausal osteoporosis (23 13, N = 86) had values
comparable to healthy adults. Circulating l,25(OH)7D3 levels
were low in surgical hypoparathyroidism (10 4, N 4) and
undetectable in patients with chronic renal failure on dialysis.
Serum PTH. This was measured by radioimmunoassay using
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Fig. 2. Cumulative calcium balance for 6 days
(mmol) in 7 patients during control (C) and
thiazide (T) period. The upper surface of each
bar is the dietary intake; the open portion of
the bar is fecal losses, and the cross-hatched
C T C I C T C T C I portion is urine losses. Values above the zeroline indicate positive balance—retention—,4 5 6 7 below the line the opposite.C T C I1 2 3
shows the line for their retentions in a ratio of 0.66 phosphate to
calcium, the ratio of calcium to phosphate in bone apatite [26].
The ratio of the mean increase in phosphate retention to the
mean increase in calcium retention was 0.58.
Serum measurements
Serum mineral, PTH, and calcitriol values (Table 3) were
unchanged by thiazide. Potassium level (mEq/liter) fell (3.99
.06 vs. 3.07
.08, P < 0.001), and pH and bicarbonate (mM)
rose (7.39 .01 vs. 7.46 .01 and 25 I vs. 29 1, both P <
0.01), reflecting the expected fall of potassium and mild meta-
bolic alkalosis [27, 28]. Control PTH levels of all seven patients
were within the normal range. Compared to age matched
normals (Methods), calcitriol levels were normal, or, in patients
4, 6, and 7 (Table 3) high.
Discussion
Chlorthalidone and trichlormethiazide increased calcium and
phosphate retentions in our seven patients with severe hyper-
calciuria. The increase for calcium resulted from two opposing
but unequal effects; calcium absorption fell, but urine calcium
losses fell more. Urine phosphate excretion fell despite a
constant intestinal absorption rate, so retention increased. The
net effect was an increased retention of both ions, in the
proportion of 0.58 phosphate to calcium; presumably the reten-
tion was in bone.
These results are like those of one other balance study [121,
and differ from the other 3 [13—IS]. Nassim and Higgins [121
report that live of seven patients given bendrofluazide increased
their calcium retention, whereas two did not; as we observed,
calcium absorption of their patients fell, but urine calcium fell
Diet Fecal Urine Net ab- Balance
loss loss sorption
25
12.5
0
—12.5
—25
Fig. 3. Mean (±5EM) differences (thiazide—control) of calcium intake,
fecal loss, urine loss, net absorption and balance in all 7 patients, in
,nmol/6 days. * Mean difference vs. 0, P < 0.05; P < 0.02; P <
0.001.
more. In another study [131, retention of calcium increased in
all four patients taking 100 mg of hydrochlorthiazide daily, but
intestinal calcium absorption increased, contrary to what we
found. Harrison and Rose found no change in fecal calcium of
five patients given bendrofluazide [14], contrary to our data and
results of Nassim and Higgins [12]; since urine calcium excre-
tion fell, and diet calcium was constant, calcium retention
increased. Donath et al [15] found that hydrochiorthiazide
increased fecal calcium losses in five normal children, contrary
to the effects of that drug in four patients with hypercalciuria
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Table 2. Urine values during control and treatment periods on fixed djets as inpatients
Pt I Pt 2 Pt 3 Pt 4 Pt 5
-—
Pt 6 Pt 7 All
Calcium C 279 27 392 9 286 22 286 13 383 16 274 18 305 100
T 129 II" 287 20" 126 17" 161 12" 136 9" 140 18" 194 11b 167 9"
Sodium C 125 13 171 13 172 10 182 16 180 5 181 12 151 II 166 5
T 130 13 163 13 177 12 175 12 163 20 161 34 152 18 160 7
Phosphate C 0.89 0.07 1.12 0.t3 1.06 0.08 1.07 0.07 1.05 .09 0.97 .08 0.94 0.03 1.02 0.03
T 0.71 0.04" 1.15 0.03 1.09 0.05 0.92 0.09 1.03 0.08 0.93 .05 0.85 0.09 0.96 0.03
Magnesium C 114 12 150 6 127 12 98 15 99 10 94 4 120 8 115 4
T 98±8 159±1! 134±12 119±5" 126±7" 92±8 114±5 120±4
Body wt C 85.5 0.1 88.1 0.1 91.7 0.1 73.6 0.2 100.7± 0.1 82.3 0.2 57.9 0.1 82.2 1.9
T 84.6 0.1" 85.8 0.1" 89.7 0.1" 72.4 0.1" 97.9 0.1" 78.7 0.3" 55.3 o.la 81.1 1.8
Volume C 1.38 0.14 2.79 0.28 2.97 0.15 4.02 0.60 1.89 0.24 3.73 0.14 2.31 0.34 2.75 0.l7
T 1.29 0.08 3.11 0.11 2.67 0.11 3,37 0.16 2.36 0.23 3.57 0.48 1.82 0.16 2.59 0.14
Calcium, phosphate are in mg/24 hour; sodium and magnesium in mEq/24 hour; body wt in kg, and volume in liter/24 hour. Data are mean SEM.
"differs from control period P < 0.00!
h differs from control period P < 0.01
"differs from control period P < 0.05
z, ,.
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[13]; it lowered their urine calcium excretions, but calcium
absorption felt much more, so calcium retention fell.
Other studies, not using the balance method, have given even
more varied results. Using one hour serum levels of radioactive
calcium following an oral load as an index of calcium absorp-
tion, Gursel [16] found that chlorthalidone reduced calcium
absorption in 10 patients with stones and hypercalciuria. Ehrig,
Harrison and Wilson [171 found that thiazide reduced calcium
absorption, as measured by double isotope technique, in tO of
22 patients with hypercalciuria and stones; absorption was
unchanged in the rest. Bendrollumethiazide increased calcium
absorption, measured by the double isotope technique, in four
of eight patients with stones reported by Jorgensen and
Transbol [18]; the other four showed no change. Barilla et al
[19] found that thiazide reduced calcium absorption in six of
eight patients with stones and hypercalciuria, who could have
had abnormal renal tubule calcium reabsorption as a cause of
hypercatciuria because they had elevated levels of either serum
parathyroid hormone (PTH) or urine cyclic AMP; absorption
did not change in 10 hypercalciuric patients with normal levels
of serum PTH and urine cyclic AMP. Absorption was estimated
by a single isotope method that indexes unidirectional uptake
into blood but not subsequent secretion from blood to intestinal
lumen, and was measured during a reduced calcium diet. The
fall in calcium absorption in high PTH patients was later
associated with a fall in serum levels of 1 ,25(OH)2D3 [29]. None
of these results can be compared directly to ours, as they
measure calcium uptake from lumen to blood, not overall
calcium absorption. But they tend to agree that calcium absorp-
tion frequently falls.
Our results differ from those in osteoporosis; given to women
with osteoporosis who were also given 25(OH)D3 to increase
their intestinal calcium absorption, thiazide reduced calcium
absorption more than it decreased urine calcium, so retention of
calcium did not increase [301. The fall in intestinal calcium
absorption was related to a fall in serum calcitriol level [30]. The
difference between that study and ours may be partly that the
absolute fall in urine calcium excretion by osteoporotic patients
was small compared to the fall in calcium absorption.
Mechanisms of reduced calcium absorption are unclear.
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Fig. 5. Mean (±5LM) differences (tb/az/dc—control) qf phosphate in-
take feca! loss, urine loss, net absorption, and balance in all 7 patients,
in m,nol/6 days. * Mean difference vs. 0: P < 0.05; ** p < 0.02.
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Fig. 4. Cumulative phosphate balance for 6 days (minol) in seven
patients during control (C) and thiazide (T) periods. Open and hatched
areas of bars as in Figure I.
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Table 3. Serum values during control and treatment periods on fixed diets as inpatients
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Calcitriol levels in blood did not fall, as they did in those
patients selected [29] for having high serum PTH levels, or in
osteoporotic women [30] given 25(OH)D3. In rats, chlor-
thalidone can reduce calcium absorption even when calcitriol
itself is given in a fixed dose sufficient to increase both absorp-
tion and urine calcium losses 120]. The latter suggests a direct
effect of the drug on the intestine independent of calcitriol, as
we suggest here.
Our findings may be specific to people with severe hypercal-
ciuria; they have so high a urine calcium excretion rate, and so
great a fall in urine calcium loss with drugs like chlorthalidone,
that modest increases in stool calcium loss are overbalanced.
They may also be specific to patients, like our seven, whose
serum PTH levels are normal, and may not apply to those
whose levels are definitely low or high. In normal adults,
children, osteoporotic patients, and patients with mild hyper-
calciuria, thiazide type diuretics may fail to increase calcium
retention because such people excrete so much less calcium in
their urine that the reduction of urine calcium loss is too small
to overbalance the fall in calcium absorption. The constancy of
our findings may well reflect our selection of severely
hypercalciuric adults as subjects. The fact that hypertensive
patients taking thiazide may have higher bone mineral density
[31] than untreated hypertensive patients or normal people is
compatible with the hypothesis that the drug increases calcium
retention in most people who take it, but by an amount too
small to detect in balance experiments.
Clinical implications of this study are best limited to people
with severe hypercalciuria and normal serum PTH levels, like
those we have studied. When given chlorthalidone, they will
retain more calcium and phosphate than they do untreated. For
them, thiazide seems an especially ideal drug.
Our study design uses each person as a control. The disad-
vantage is that altered diet during the balance measurements
could cause a change in eating habits that would influence long
term behavior, and therefore potentially affect mineral balance
independent of the chlorthalidone. The advantage is reducing
effects of the natural variation between people. We were
fortunate, in that our patients were probably eating more
calcium by free choice than during our protocol, since urine
calcium excretions fell. Urine sodium excretion also fell, so this
inference is not very strong. Even so, a fall in intake would not
have increased calcium retention, as lowering calcium intake is
not known to have such effects.
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T — 1.149 — 0.940 1.067 1.171 1.120 1.09 0.04
Caicitriol C 21.3 0.5 30.8 5.5 14.5 1.6 44.4 2.5 32.5 2.7 42.5 1.8 44.4 7.3 33.5 2.8
T 20.4 1.2 20.0 0.8 20.5 3.1 38.1 1.3 21.3 2.3 49.3 2.9 41.9 2.1 30.2 2.7
Abbreviations are: Pt, patient; C, control period; T, treatment period; Ion Ca, ionized calcium.
Calcium, phophate, magnesium, potassium and ionized calcium in mg/dl; calcitriol in pm/dl; PTH in pm/mi.
C vs. T, P < 0.02.
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Fig. 6. Calcium balance vs. phosphate balance in all 7 patients during
control (closed circle) and thiazide (open circle) periods. Patient
numbers are shown (Table I). The line depicts a ratio of phosphate to
calcium balance of 0.66, the ratio in bone mineral apatile.
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